


Aberrant regulation of mitotic exit in cancer due to RB1 defects



Dick, FA., Orlic-Milacic, M.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](https://creativecommons.org/licenses/by/4.0/). For more information see our [license](https://reactome.org/licenses/).

This is just an excerpt of a full-length report for this pathway. To access the complete report, please download it at the [Reactome Textbook](https://reactome.org/textbook/).

28/04/2024

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)


Reactome database release: 88

This document contains 1 pathway and 1 reaction ([see Table of Contents](#))

Aberrant regulation of mitotic exit in cancer due to RB1 defects ↗

Stable identifier: R-HSA-9687136

Diseases: cancer



RB1 regulates mitotic exit by acting on SKP2, a component of the SCF E3 ubiquitin ligase complex. RB1 facilitates degradation of SKP2 by the anaphase promoting complex/cyclosome (APC/C), thus preventing SKP2-mediated degradation of the cyclin-dependent kinase inhibitor CDKN1B (p27Kip1). RB1-dependent accumulation of p27Kip1 plays an important role in mitotic exit and RB1-mediated tumor suppression (reviewed by Dyson 2016).

Literature references

Dyson, NJ. (2016). RB1: a prototype tumor suppressor and an enigma. *Genes Dev.*, 30, 1492-502. ↗

Editions

2020-05-07	Authored	Orlic-Milacic, M.
2020-05-17	Reviewed	Dick, FA.
2020-05-18	Edited	Orlic-Milacic, M.

Defective RB1 does not form a complex with SKP2 and FZR1 ↗


Location: [Aberrant regulation of mitotic exit in cancer due to RB1 defects](#)

Stable identifier: R-HSA-9687377

Type: transition

Compartments: cytosol

Diseases: cancer



A tripartite complex formed between RB1, SKP2 and FZR1 (Cdh1) targets SKP2 for the anaphase promoting complex/cyclosome (APC/C:Cdh1)-mediated ubiquitination and subsequent proteasome-mediated degradation. Both SKP2 and FZR1 interact with the pocket domain of RB1, with amino acid residues 637–738 and 772–824 involved in SKP2 binding and the cleft region (amino acids 753–761), containing the LxCxE motif, involved in FZR1 binding (Binne et al. 2007). RB1 T738_R775del (RB1 Ex22del) cancer mutant, which lacks exon 22, is able to associate with SKP2 but unable to bind FZR1. This mutant is defective in inducing accumulation of CDKN1B (p27Kip1) and promoting mitotic exit as it cannot prevent SKP2-mediated ubiquitination and degradation of CDKN1B (Ji et al. 2004, Binne et al. 2007). RB1 T738_R775del mutant is also defective in E2F binding (Ji et al. 2004). RB1 missense mutant, RB1 R661W, which causes low penetrance familial retinoblastoma, is unable to bind to E2Fs but retains the ability to bind to SKP2 and FZR2 and to induce CDKN1B accumulation (Ji et al. 2004, Binne et al. 2007).

Literature references

Ji, P., Rekhman, K., Pagano, M., Bloom, J., Jiang, H., Zhu, L. et al. (2004). An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. *Mol. Cell*, 16, 47-58. ↗

Binné, UK., Kaelin, WG., Rape, M., Classon, MK., Wei, W., Dyson, NJ. et al. (2007). Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. *Nat. Cell Biol.*, 9, 225-32. ↗

Editions

2020-05-07	Authored	Orlic-Milacic, M.
2020-05-17	Reviewed	Dick, FA.
2020-05-18	Edited	Orlic-Milacic, M.

Table of Contents

Introduction	1
❖ Aberrant regulation of mitotic exit in cancer due to RB1 defects	2
⌘ Defective RB1 does not form a complex with SKP2 and FZR1	3
Table of Contents	4